Ikarugamycin

Ikarugamycin is an unsual pentacyclic tetramic acid produced by Streptomyces phaeochromogenes with potent activity against the protozoan, Trichomonas vaginalis, reported in 1972. Ikarugamycin also demonstrated selective Gram positive antibacterial activity and more recently has been shown to exhibit anti-ulcer activity possibly by inhibition of Helicobacter. Investigation of the pharmacology of ikarugamycin has demonstrated a variety of actions including the inhibition of the uptake of oxidized low-density lipoprotein in mouse macrophages, blockade of PMA and Nef-mediated cell surface CD4 down-regulation and inhibition of clathrin-coated pit-mediated endocytosis. Importantly, ikarugamycin is emerging as a useful \nagent for studying the process of endocytosis. \n\nSource: Streptomyces sp.\n\nApperance: White solid\n\nSolubility: Soluble in ethanol, methanol, DMF or DMSO. Limited water solubility.\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage store at -20 degrees C. Aliquots are stable for at least 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I2300-20

Size

500ug

Purity

~99%

References

1. A new antibiotic, ikarugamycin. Jomom K. et al., J. Antibiot. 1972, 25, 271. 2. Inhibition of the uptake of oxidized low-density lipoprotein in macrophage J774 by the antibiotic ikarugamycin. Hasumi K. et al., Eur. J. Biochem. 1992, 205, 841. 3. Human immunodeficiency virus type 1 Nef-induced CD4 cell surface downregulation is inhibited by ikarugamycin. Luo T. et al., J. Virol. 2001, 75, 2488. 4. Distinct endocytic pathways identified in tobacco pollen tubes using charged nanogold. Moscatelli A. et al., J. Cell Sci. 2007, 120, 3804.